News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA: Boehringer Ingelheim Corporation's Pradaxa Benefit Outweighs Bleeding Risk


12/8/2011 8:48:49 AM

Alexza Pharmaceuticals Inc.'s (ALXA: News ) inhalation antipsychotic drug candidate Adasuve poses a significant risk of bronchospasm, particularly in patients with asthma and chronic obstructive pulmonary disease, according to FDA briefing documents posted online yesterday. Adasuve is a drug-device combination which uses Alexza's proprietary Staccato system to deliver the antipsychotic Loxapine into the patient's lungs. Alexza is seeking approval for Adasuve for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder. This is Adasuve's second go-around with the FDA.

Read at RTT News
Read at ABC News
Read at News Release
Read at Forbes

comments powered by Disqus
   
Bleeding

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES